| 期刊論文| 1. | Ormerod, L. P.、Horsfield, N.(1996)。Frequency and type of reactions to antituberculosis drugs: observations in routine treatment。Tubercle and Lung Disease，77(1)，37-42。   | | 2. | 高嘉宏、陳定信(19980600)。C型肝炎在臺灣。中華公共衛生雜誌，17(3)，191-197。 延伸查詢 | | 3. | Raviglione, M. C.、Dye, C.、Schmidt, S.、Kochi, A.(1997)。Assessment of worldwide。Lancet，350，624-629。 | | 4. | Raviglione, M. C.、Snider, D. E.、Kochi, A.(1995)。Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic。JAMA，273，220-226。 | | 5. | Centers for Disease Control and Prevention(2003)。Treatment of tuberculosis, American Thoracic Society, CDC, and Infectious Diseases Society of America。MMWR，52(2)，1-77。 | | 6. | 盧俊良、陳祖裕(19940800)。B型肝炎之概況。臨床醫學，34(2)=200，85-98。 延伸查詢 | | 7. | Dossing, M.、Wilcke, J. T. R.、Askgaard, D. S.、Nybo, B.(1996)。Liver injury during antituberculosis treatment: an 11-year study。Tuber Lung Dis，77，335-340。 | | 8. | CDC(2003)。Update: Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States。MMWR，52(31)，735-738。 | | 9. | Hwang, S. J.、Wu, J. C.、Lee, C. N.(1997)。Drug-induced liver disease: a prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B。J Gastroenterol Hepatol，12，87-91。 | | 10. | Amarapurkar, D. N.、Prabhudesai, P. P.、Kalro, R. H.、Desai, H. G.(1993)。Antituberculosis drug-induced hepatitis and HBsAg carriers。Tuber Lung Dis，74，215-216。 | | 11. | Wu, J. C.、Lee, S. D.、Yeh, P. F.(1990)。Isoniazid-rifampin-induced hepatitis in hepatitis B carriers。Gastroenterology，98，502-504。 | | 12. | Huang, Y. S.、Chem, H. D.、Su, W. J.(2002)。Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis。Hepatology，35，883-889。 | | 13. | McNeill, L.、Allen, M.、Estrada, C.(2003)。Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity。Chest，123，102-106。 | | 14. | American Thoracic Society, Centers for Disease Control and Prevention, Infectious Disease Society of American(2003)。Treatment of tuberculosis。Am J Respir Crit Care Med，167，603-662。 | | 15. | Durand, F.、Jebrak, G.、Pessayre, D.、Fournier, M.、Bernuau, J.(1996)。Hepatotoxicity of antitubercular treatments: rationale for monitoring liver status。Drug Safety，15(6)，394-405。 | 圖書| 1. | World Health Organization(2003)。Treatment of tuberculosis: guidelines for national programmes。Geneva：WHO Global Tuberculosis Programme。 | | 2. | 陸坤泰(2004)。結核病診治指引。台北：行政院衛生署疾病管制局。 延伸查詢 | | 3. | (2005)。DrugDex: under the title of pyrazinamide, isoniazid, rifampin, ethambutol。Micromedex Inc.。 | |